Search Results

Tranquis Therapeutics announced that members of its management team will participate in the following investor conferences in March 2022:

Tranquis Therapeutics, Inc. today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1 a, at ARDD 2022, the 9th Aging Research and Drug Discovery meeting, taking place August 29 to September 2, 2022 at the University of Copenhagen, Denmark.

Tranquis plans to start a Phase 2 trial in people living with ALS by the end of 2022.

Tranquis Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of TQS-168 in healthy volunteers.

Tranquis Therapeutics announced its CEO, Sanjak Kakkar, M.D. will give a corporate presentation at the Biotech Showcase, being held January 10-19, 2022.

Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Tranquis Therapeutics, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).